Published in Hepatitis Weekly, October 4th, 2004
The study, involving 35 healthy volunteers and conducted in Europe, was designed to assess safety, tolerability and pharmacokinetics in escalating, single doses of VX-950.
Based on the results from this study and preclinical studies, the company expects to begin a phase 1b clinical study of VX-950 in HCV-infected patients by the end of the year.
In the phase 1a study, single doses ranging from 25 mg to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.